With a strategy similar to HVP IV, Hatteras Venture Partners V (HVP V), and its related parallel funds, has over $170 million in available capital. The fund will build on the successful seed-stage initiative of HVP IV, Hatteras Discovery, an allocation of the fund focused on seed-stage companies and projects in the field of human medicine and life sciences.  HVP V will invest in a range of human medicine companies across the US, with an emphasis on leading company formations in the technology rich southeast region.

  • Stride Biosciences, Inc.

    Stride Biosciences, Inc.

    StrideBio was founded based on technologies and intellectual property from Dr. Aravind Asokan’s lab at the University of North Carolina at Chapel Hill and Dr. Mavis Agbangje-McKenna’s lab at the University of Florida. Stride is developing engineered viral vectors for gene therapy using structure-inspired design of adeno-associated virus (AAV) vectors that can evade neutralizing antibodies, a current limitation of existing gene therapies.

  • Boston Immune Technologies & Therapies

    Boston Immune Technologies & Therapies

    Boston Immune Technologies & Therapeutics (BITT) is a Boston-based biopharmaceutical company developing immune-based approaches for the treatment of cancer and infectious diseases. BITT was founded based on research and intellectual property from Dr. Denise Faustman’s lab at Massachusetts General Hospital/Harvard Medical School and is developing a TNFR2 antagonist to channel the power of the immune system into fighting cancer.

  • NurseGrid


    NurseGrid employs a bottoms up, mobile-first solution through a free app for scheduling and shift management for nurses and health techs. NurseGrid is made up of a passionate team of business leaders, engineers, designers, and nurses striving to create more workplace engagement and productivity in nursing departments across the country. Focused on the intersection of healthcare and technology, the Company is bringing innovative technology to the healthcare space quickly and seamlessly.

  • Ribometrix, Inc.

    Ribometrix, Inc.

    Ribometrix is a platform therapeutics company based on research out of UNC-Chapel Hill. With the conviction that numerous diseases could be cured and lives of countless people could be improved by changing the behavior of disease-causing RNA, the Company is focused on completely changing the landscape of disease treatment by discovering small molecule drugs that target RNA structures.

  • Genturi


    Based on research from Dr. Mike Ramsey’s lab at UNC-CH, Genturi is developing a fully integrated microfluidics genomic sequencing platform for the rapid delivery of low-cost genomic maps for clinical and non-clinical applications.

  • Artizan Biosciences

    Artizan Biosciences

    Artizan Biosciences is developing therapeutic vaccines that can eliminate disease-causing bacteria in the gut microbiome. Artizan leverages its proprietary platform technology called IgA-SEQ™ to uncover and characterize the “bad-actor” bacteria in various diseases, with an initial focus on Inflammatory Bowel Disease (Crohn’s & Colitis). The technology was developed in the labs of Richard Flavell and Noah Palm at Yale University, and has been exclusively licensed to Artizan Biosciences.

  • Rodin Therapeutics

    Rodin Therapeutics

    Based out of Cambridge, MA, Rodin Therapeutics is discovering and developing first-in-class therapeutics for neurological disorders such as Alzheimer’s, applying unique insights into the role of epigenetics and novel chemical strategies to target specific HDAC complexes. Rodin’s novel approach promotes synaptic resilience, with the goal of targeting the cause of cognitive impairment, restoring expression of synaptic genes, and ultimately improving brain function.

  • Trefoil Therapeutics

    Trefoil Therapeutics

    Trefoil was founded to bring forward novel engineered FGF-1 compounds to treat endothelial cell mediated diseases. The initial development program is focused on treating a serious ophthalmic disease, Fuchs’ Dystrophy which is a leading cause of corneal transplantations. This disease has limited treatment options other than surgery and there is a large unmet need for therapeutic agents that can offer patients other therapeutic options.

  • Bivarus


    Bivarus brings an entirely new science of measuring the patient experience with its patented cloud-based analytics platform. Measuring and improving the patient experience has become one of the top priorities of the healthcare system, and Bivarus is redefining how healthcare leaders capture and operationalize patient-generated insights to improve patient care and service operations. Organizations rely on Bivarus’ real-time analytics platform to gain meaningful insights into the unique drivers impacting the patient experience, buying behavior and provider performance.

  • Medfusion


    Medfusion delivers transformative technology and services that put patients in control of their healthcare and enable providers to thrive in a value-based healthcare delivery environment. Their patient portal, evolving platform and mobile capabilities connect more than 11 million patients to their healthcare providers—facilitating bi-directional communication, enhancing patient engagement and improving the practice’s financial operations.

  • Qvella


    Qvella is a molecular diagnostics company founded by a group of scientists and engineers with the simple goal of dramatically reducing time to results in bacteriology. Qvella’s Field Activated Sample Treatment (FAST)technology utilizes a novel electrical lysing and sample treatment technique enabling rapid detection of infectious agents in a direct blood sample. When implemented in concert with Antibiotic Stewardship programs, now being adopted by most major medical centers, timely clinical decisions can be made which lead to improved patient outcomes, reduced hospital stays, lower side effect profiles, and a significant reduction in treatment costs.